- Home
- REGN vs MRVL Comparison
REGN vs MRVL Comparison
Compare REGN & MRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MRVL
- Stock Information
- Founded
- REGN 1988
- MRVL 1995
- Country
- REGN United States
- MRVL United States
- Employees
- REGN N/A
- MRVL N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MRVL Semiconductors
- Sector
- REGN Health Care
- MRVL Technology
- Exchange
- REGN Nasdaq
- MRVL Nasdaq
- Market Cap
- REGN 110.0B
- MRVL 108.0B
- IPO Year
- REGN 1991
- MRVL 2000
- Fundamental
- Price
- REGN $700.33
- MRVL $103.79
- Analyst Decision
- REGN Buy
- MRVL Strong Buy
- Analyst Count
- REGN 26
- MRVL 28
- Target Price
- REGN $996.00
- MRVL $118.96
- AVG Volume (30 Days)
- REGN 905.6K
- MRVL 14.0M
- Earning Date
- REGN 02-04-2025
- MRVL 03-05-2025
- Dividend Yield
- REGN 0.13%
- MRVL 0.23%
- EPS Growth
- REGN 10.27
- MRVL N/A
- EPS
- REGN 38.34
- MRVL N/A
- Revenue
- REGN $14,202,000,000.00
- MRVL $5,376,400,000.00
- Revenue This Year
- REGN $5.20
- MRVL $6.32
- Revenue Next Year
- REGN $6.39
- MRVL $42.26
- P/E Ratio
- REGN $18.27
- MRVL N/A
- Revenue Growth
- REGN 8.27
- MRVL N/A
- 52 Week Low
- REGN $642.00
- MRVL $53.19
- 52 Week High
- REGN $1,211.20
- MRVL $127.48
- Technical
- Relative Strength Index (RSI)
- REGN 52.55
- MRVL 42.72
- Support Level
- REGN $655.85
- MRVL $100.22
- Resistance Level
- REGN $689.95
- MRVL $112.50
- Average True Range (ATR)
- REGN 21.25
- MRVL 5.12
- MACD
- REGN 2.98
- MRVL -0.66
- Stochastic Oscillator
- REGN 63.22
- MRVL 16.54
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.